Literature DB >> 2169345

In situ distribution of the beta-subunit of platelet-derived growth factor receptor in nonneoplastic tissue and in soft tissue tumors.

W A Franklin1, W H Christison, M Colley, A G Montag, J K Stephens, C E Hart.   

Abstract

The distribution of the beta-subunit of platelet-derived growth factor receptor (PDGFR-beta) was assessed by a sensitive immunoalkaline phosphatase technique using the monoclonal antibody PR7212. Frozen tissue sections of several nonneoplastic human tissues were stained along with 42 soft tissue sarcomas, 16 benign soft tissue proliferations, and 7 epithelial tumors. In all nonneoplastic tissue, there was intense labeling of cell processes of perivascular fibroblasts or pericytes in and about the walls of muscular blood vessels and of fibroblast cell processes around some glandular and ductal epithelia. No PDGFR-beta was found in the endothelial cells of muscular arteries and veins, but cells of uncertain identity within some capillaries were immunoreactive and the possibility that endothelial cells of some small capillaries express PDGFR-beta could not be excluded. In kidney there was strong labeling of glomerular mesangial cells and interstitial fibroblasts. Some histological types of soft tissue sarcomas were uniformly and strongly labeled with anti-PDGFR-beta, but other types were infrequently labeled or unreactive. The order of decreasing frequency and strength of labeling of the various types of benign and malignant soft tissue proliferations was as follows: benign fibromatosis and neurofibroma greater than malignant fibrous histiocytoma greater than liposarcoma greater than leiomyosarcoma greater than rhabdomyosarcoma. No tumor cell labeling was detected in epithelioid, synovial or clear cell sarcomas, leiomyomas, or carcinomas, but there was usually strong labeling of fibroblast and/or pericyte cell processes within tumor, especially around blood vessels. We conclude that PDGFR-beta is strongly expressed by vascular and stromal tissues of most tumors and normal organs and by tumor cells of several types of soft tissue tumors and proliferations, most notably those of fibroblastic origin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2169345

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.

Authors:  Margaret von Mehren; Cathryn Rankin; John R Goldblum; George D Demetri; Vivien Bramwell; Christopher W Ryan; Ernest Borden
Journal:  Cancer       Date:  2011-07-12       Impact factor: 6.860

Review 2.  Developmental definition of MSCs: new insights into pending questions.

Authors:  Shishu Huang; Victor Leung; Songlin Peng; Laiching Li; Feng Juan Lu; Ting Wang; William Lu; Kenneth M C Cheung; Guangqian Zhou
Journal:  Cell Reprogram       Date:  2011-09-15       Impact factor: 1.987

3.  Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents.

Authors:  Minfeng Chen; Xueping Lei; Changzheng Shi; Maohua Huang; Xiaobo Li; Baojian Wu; Zhengqiu Li; Weili Han; Bin Du; Jianyang Hu; Qiulin Nie; Weiqian Mai; Nan Ma; Nanhui Xu; Xinyi Zhang; Chunlin Fan; Aihua Hong; Minghan Xia; Liangping Luo; Ande Ma; Hongsheng Li; Qiang Yu; Heru Chen; Dongmei Zhang; Wencai Ye
Journal:  J Clin Invest       Date:  2017-08-28       Impact factor: 14.808

4.  Expression of platelet-derived growth factor receptors in normal and diseased human kidney. An immunohistochemistry and in situ hybridization study.

Authors:  L Gesualdo; S Di Paolo; S Milani; M Pinzani; C Grappone; E Ranieri; G Pannarale; F P Schena
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

5.  Expression of growth factor receptors, the focal adhesion kinase, and other tyrosine kinases in human soft tissue tumors.

Authors:  T M Weiner; E T Liu; R J Craven; W G Cance
Journal:  Ann Surg Oncol       Date:  1994-01       Impact factor: 5.344

Review 6.  Antibody-directed targeting of the vasculature of solid tumors.

Authors:  P E Thorpe; F J Burrows
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

7.  Localization of mesenchymal cells in adult mouse thymus: their abnormal distribution in mice with disorganization of thymic medullary epithelium.

Authors:  Chikako Odaka
Journal:  J Histochem Cytochem       Date:  2008-12-24       Impact factor: 2.479

8.  Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates.

Authors:  Janelle M Meyer; Kelly S Perlewitz; James B Hayden; Yee-Cheen Doung; Arthur Y Hung; John T Vetto; Rodney F Pommier; Atiya Mansoor; Brooke R Beckett; Alina Tudorica; Motomi Mori; Megan L Holtorf; Aneela Afzal; William J Woodward; Eve T Rodler; Robin L Jones; Wei Huang; Christopher W Ryan
Journal:  Clin Cancer Res       Date:  2013-10-16       Impact factor: 12.531

9.  Gas6 derived from cancer-associated fibroblasts promotes migration of Axl-expressing lung cancer cells during chemotherapy.

Authors:  Ryu Kanzaki; Hisamichi Naito; Kazuyoshi Kise; Kazuhiro Takara; Daisuke Eino; Masato Minami; Yasushi Shintani; Soichiro Funaki; Tomohiro Kawamura; Toru Kimura; Meinoshin Okumura; Nobuyuki Takakura
Journal:  Sci Rep       Date:  2017-09-06       Impact factor: 4.379

10.  New drugs and combinations for the treatment of soft-tissue sarcoma: a review.

Authors:  Neeta Somaiah; Margaret von Mehren
Journal:  Cancer Manag Res       Date:  2012-11-23       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.